SYRE Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Spyre Therapeutics's net margin of -49.65%. Spyre Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Spyre Therapeutics has a consensus price target of $43.14, signalling upside risk potential of 161.02%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 434.43%. Given that NovaBay Pharmaceuticals has higher upside potential than Spyre Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Spyre Therapeutics.

Spyre Therapeutics has a beta of 2.860, which suggesting that the stock is 185.983% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Spyre Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Spyre Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Spyre Therapeutics's net income of -$69M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Spyre Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics is 771.72x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Spyre Therapeutics's net margin of -2357.27%. Spyre Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

Spyre Therapeutics has a consensus price target of $43.14, signalling upside risk potential of 161.02%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1404.43%. Given that Palatin Technologies has higher upside potential than Spyre Therapeutics, analysts believe Palatin Technologies is more attractive than Spyre Therapeutics.

Spyre Therapeutics has a beta of 2.860, which suggesting that the stock is 185.983% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Spyre Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Spyre Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Spyre Therapeutics's net income of -$69M is lower than Palatin Technologies's net income of -$7.8M. Notably, Spyre Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics is 771.72x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Rocket Pharmaceuticals has a net margin of -- compared to Spyre Therapeutics's net margin of --. Spyre Therapeutics's return on equity of -- beat Rocket Pharmaceuticals's return on equity of --.

Spyre Therapeutics has a consensus price target of $43.14, signalling upside risk potential of 161.02%. On the other hand Rocket Pharmaceuticals has an analysts' consensus of $43.13 which suggests that it could grow by 287.19%. Given that Rocket Pharmaceuticals has higher upside potential than Spyre Therapeutics, analysts believe Rocket Pharmaceuticals is more attractive than Spyre Therapeutics.

Spyre Therapeutics has a beta of 2.860, which suggesting that the stock is 185.983% more volatile than S&P 500. In comparison Rocket Pharmaceuticals has a beta of 1.007, suggesting its more volatile than the S&P 500 by 0.72700000000001%.

Spyre Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rocket Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics pays -- of its earnings as a dividend. Rocket Pharmaceuticals pays out -- of its earnings as a dividend.

Spyre Therapeutics quarterly revenues are --, which are smaller than Rocket Pharmaceuticals quarterly revenues of --. Spyre Therapeutics's net income of -$69M is lower than Rocket Pharmaceuticals's net income of -$66.7M. Notably, Spyre Therapeutics's price-to-earnings ratio is -- while Rocket Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics is 771.72x versus -- for Rocket Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Spyre Therapeutics's net margin of --. Spyre Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

Spyre Therapeutics has a consensus price target of $43.14, signalling upside risk potential of 161.02%. On the other hand Theriva Biologics has an analysts' consensus of -- which suggests that it could grow by 6141.38%. Given that Theriva Biologics has higher upside potential than Spyre Therapeutics, analysts believe Theriva Biologics is more attractive than Spyre Therapeutics.

Spyre Therapeutics has a beta of 2.860, which suggesting that the stock is 185.983% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.367%.

Spyre Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Spyre Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Spyre Therapeutics's net income of -$69M is lower than Theriva Biologics's net income of -$7.7M. Notably, Spyre Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics is 771.72x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.